全国同城凤凰楼信息茶楼_51pcmc品茶2024官网_全国兼职凤凰楼信息

Biography

Dr. Lin graduated from the School of Life Sciences, Beijing Institute of Technology in 2010, and obtained his PhD from the University of Saskatchewan School of Medicine in Canada 2014. After graduating from his Ph.D, he started his post-doctoral training at the Ottawa Heart Institute. His supervisor, Dr. Peter Liu was an authoritative Canadian cardiologist and professor at the University of Toronto School of Medicine. He is mainly engaged in the research of cardiac pathology, pharmacology and immunology. The current research includes exploring the key role of immune factor signaling pathways in the pathogenesis of heart disease, and the use of proteomics to screen biomarker for cardiovascular diseases. Dr. Lin joined Zhongshan Institute for Drug Discovery, the Institutes of Drug Discovery and Development, CAS as Principal Investigator in 2021.

Research Directions

Pharmacology、Pathology、Proteomics、Metabonomics、Immunology、Cardiovascular system

Achievements

During his Ph.D study, he used proteomics to study the pathological and pharmacological mechanisms of heart disease, he was selected as one of the 20 outstanding young researchers in 2012 by the Canadian Cardiovascular Society (CCS) and awarded Have A Heart Bursary, and became a member of the Canadian Cardiovascular Society. Post-doctoral research mainly included exploring the key role of innate immune factor signaling pathways in the pathogenesis of heart disease, and using proteomics methods to screen biomarker for cardiovascular diseases. In 2017 he won the Young Investigator Award from the European Society of Cardiology Congress 2017.

Publications

1.Jiawei Zhanga, Yijing Songa, You Lia, Han-Bin Lin, Xuexian Fanga. Iron Homeostasis in the Heart: Molecular Mechanisms and Pharmacological Implications.JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY.(In press)

 

2.Li Feng, Yue Wang, Jian Yang, Yi-fan Sun, Yi-wei Li, Zi-hong Ye, Han-bin Lin, Ke Yang.Overview of the preparation method, structure and function, and application of natural peptides and polypeptides. Biomedicine & Pharmacotherapy,Volume 153,2022,113493.

 

3.Ke Yang, Yue Wang, Yi-wei Li, Yi-gong Chen, Na Xing, Han-bin Lin, Ping Zhou, Xiao-ping Yu,Progress in the treatment of diabetic peripheral neuropathy, Biomedicine & Pharmacotherapy,Volume 148, 2022, 112717.

 

4.Yang ke, Huang Jian-yuan, Zhou ping, Wang yue, Xing Na, Yang Jian, Lin Kai-xuan, Sun Yi-fan, Han-Bin Lin, Li Rong. The progressive application of single cell RNA sequencing technology in cardiovascular diseases. Biomedicine & Pharmacotherapy,2022.

 

5.Han-Bin Lin, PhD and Peter P. Liu, MD. (2020). COVID-19 and the Heart, ACE2 Level and the Company it Keeps Hold the Key. JACC: Basic to Translational Science. 5(9): 884-887.

 

6.Han-Bin Lin, PhD; Kotaro Naito, MD, PhD; Yena Oh, MSc, Gedaliah Farber; BHSc, Georges Kanaan, PhD, Alan Valaperti, PhD; Fayez Dawood, DVM; Liyong Zhang, PhD; Guo Hua Li, MD, PhD; David Smyth, PhD; Mark Moon, MSc; Youan Liu, MD; Wenbin Liang, PhD; Benjamin Rotstein, PhD; Dana Philpott, PhD; Kyoung-Han Kim, PhD; Mary-Ellen Harper, PhD; Peter P Liu, MD. (2020). Innate immune Nod1/RIP2 signaling is essential for cardiac hypertrophy, - but requires mitochondrial antiviral signaling protein (MAVS) for signal transductions and energy balance.

 

7. Michael A. J. Moser, Steve Arcand, Han-Bin Lin, Chris Wojnarowicz, Jolanta Sawicka Tamalina Banerjee, Yigang Luo, Gavin R. Beck, Patrick P. Luke, and Grzegorz Sawicki. (2016). Protection of the Transplant Kidney from Preservation Injury by Inhibition of Matrix Metalloproteinases.PLoS One. 11(6): 0-0.

 

8. Iwona Bil-Lula, Han-Bin Lin, Dariusz Biay, Magdalena Wawrzyska, Lucas Diebel, Jolanta Sawicka, Mieczyslaw Wo?niak, Grzegorz Sawicki. (2016). Subthreshold nitric oxide synthase inhibition improves synergistic effects of subthreshold MMP-2/MLCK-mediated cardiomyocyte protection from hypoxic injury. Journal of Cellular and Molecular Medicine. 20(6): 1086–1094.

 

9. Han-Bin Lin, Virgilio J. J. Cadete, Bikramjit Sra, Jolanta Sawicka, Zhicheng Chen, Lane K. Bekar, Francisco Cayabyab, Grzegorz Sawicki. (2014). Inhibition of MMP-2 expression with siRNA increases baseline cardiomyocyte contractility and protects against simulated ischemic reperfusion injury. BioMed Research International. 2014: 11.

 

10. Han-Bin Lin, Keshav Sharma, Dariusz Bialy, Magdalena Wawrzynska, Randy Purves, Francisco Cayabyab, Mieczyslaw Wozniak, Grzegorz Sawicki. (2014). Inhibition of MMP-2 expression affects the levels of metabolic enzymes: Proteomic analysis of rat cardiomyocytes. Journal of Proteomics. 106(25): 74-85.

 

11. Virgilio J. J. Cadete, Steven Arcand, Han-Bin Lin, Grzegorz Sawicki. (2013). Synergy in protection against cardiac ischemia/reperfusion injury: a novel therapeutic paradigm for the future. Future Medicinal Chemistry. 5(4): 389-398.

 

12. Lin Han-Bin*,Cadete Virgilio JJ*, Sawicka Jolanta, Wozniak Mieczyslaw, Sawicki Grzegorz. (2012). Proteomic analysis of right and left cardiac ventricles under aerobic conditions and after ischemia/ reperfusion.Proteomics. 12(14): 2366-2377.

 

13. Lin Han-Bin, Cadete Virgilio JJ, Sawicka Jolanta, Wozniak Mieczyslaw, Sawicki Grzegorz. (2012). Effect of the myosin light chain kinase inhibitor ML-7 on the proteome of hearts subjected to ischemia/reperfusion injury. Journal of Proteomics. 75(17): 5386-5395.